Rigel Pharmaceuticals, Inc. (RIGL) News
Filter RIGL News Items
RIGL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RIGL News Highlights
- RIGL's 30 day story count now stands at 3.
- Over the past 11 days, the trend for RIGL's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- NBIX are the most mentioned tickers in articles about RIGL.
Latest RIGL News From Around the Web
Below are the latest news stories about Rigel Pharmaceuticals Inc that investors may wish to consider to help them evaluate RIGL as an investment opportunity.
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2021 Financial Results and Business UpdateRigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2021 financial results after market close on Tuesday, March 1, 2022. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time (1:30pm Pacific Time) to discuss the financial results and give an update on the business. |
Is There An Opportunity With Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 25% Undervaluation?Does the February share price for Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) reflect what it's really worth? Today, we... |
Neurocrine Biosciences (NBIX) Reports Q4 Loss, Misses Revenue EstimatesNeurocrine (NBIX) delivered earnings and revenue surprises of -113.11% and 1.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Shareholders in Rigel Pharmaceuticals (NASDAQ:RIGL) are in the red if they invested a year agoInvestors can approximate the average market return by buying an index fund. When you buy individual stocks, you can... |
Hedge Funds Are Crazy About Rigel Pharmaceuticals, Inc. (RIGL)In this article we are going to use hedge fund sentiment as a tool and determine whether Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a good investment right now. |
Rigel (RIGL) Gets a Buy Rating from H.C. WainwrightIn a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Rigel (RIGL – Research Report), with a price target of $11.00. The company's shares closed last Monday at $2.47, close to its 52-week low of $2.30. According to TipRanks.com, Pantginis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.7% and a 27.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals. Currently, the analyst consensus on Rigel is a Strong Buy with an average price target of $8.67. |
Rigel Pharmaceuticals Provides Business UpdateSOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today provided a business update including preliminary 2021 full-year total revenue, the status of the Phase 3 study in COVID-19, and upcoming catalysts in |
Rigel down as it expects slight decrease in products sales in Q4 compared to prior yearShares of Rigel Pharmaceuticals are down today as the company announced that its Q4 2021 net product sales would be down slightly from where it was in the year-ago period. |
Rigel to Present at the J.P. Morgan Healthcare ConferenceRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the 40th Annual J.P. Morgan Healthcare Conference at 10:30 a.m. ET on Wednesday, January 12, 2022. |
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif. , Jan. 7, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL ) today reported the grant of stock options to purchase an aggregate of 610,000 shares of common stock to 14 newly hired employees. These awards were approved by the Compensation Committee of Rigel''s Board of Directors and granted pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, as amended, with a grant date of January 6, 2022 , as an inducement material to the new employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). The stock options have an exercise price of $2.62 per share, the price at the close of trading of Rigel''s common stock on January 6, 2022 . The stock options awards vest over a four-year period, with one-fourth of th... |